A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1664 participants.
Also called NCT05254002
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 1,664 participants
- Sponsor
- Registry
-
NCT05254002 -
2023-506981-30-00 -
2021-003037-11
-
- Other papers using this trial's data
- Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone
- COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics
- Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
- Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial
- Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure
- Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, Denmark, France, Germany, India, Israel, Italy, Japan, Netherlands, South Korea, Spain, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT05254002. Randomized; quadruple masking; primary purpose treatment. Start 2022-06-23 (actual); primary completion 2025-03-14 (actual). Results posted on 2026-07-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
- Acronym
- CONFIDENCE
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Finerenone (BAY94-8862 ) 10 mg
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Empagliflozin Placebo
- Intervention (Drug)
- Finerenone (BAY94-8862 ) 20 mg
- Intervention (Drug)
- Finerenone Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct05254002- Content hash
68ff3b198ca60c735dec4f3ae6a372bd2eb0d96ab5194d5c124af847b73a6ead